Clinical trials
Terminated Phase 2 Squamous Cell Carcinoma of Head and Neck trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
76 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 3 |
| 2006 | 6 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 4 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 6 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 9 |
| 2019 | 6 |
| 2020 | 1 |
| 2021 | 8 |
| 2022 | 1 |
| 2023 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 76 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 6 |
| National Cancer Institute (NCI) | 4 |
| Roswell Park Cancer Institute | 3 |
| SWOG Cancer Research Network | 3 |
| Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2 |
| Julie E. Bauman, MD, MPH | 2 |
| MacroGenics | 2 |
| Regeneron Pharmaceuticals | 2 |
| SynCore Biotechnology Co., Ltd. | 2 |
| University of Arizona | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Squamous Cell Carcinoma of Head and Neck | 76 |
| Head and Neck Neoplasms | 25 |
| Carcinoma, Squamous Cell | 7 |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Neoplasm Metastasis | 5 |
| Oropharyngeal Neoplasms | 5 |
| Recurrence | 5 |
| Melanoma | 4 |
| Mouth Neoplasms | 4 |
| Mucositis | 3 |
Trials
Showing 1 to 25 of 76. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.